Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse til at sammenligne effektiviteten, sikkerheden og tolerabiliteten af ​​FF/UMEC/VI med FF/VI hos 12-17-årige med astma

3. november 2026 opdateret af: GlaxoSmithKline

En fase 3, 24-ugers, randomiseret, dobbeltblind, parallel-gruppe Bayesiansk dynamisk låneundersøgelse, der sammenligner effektiviteten, sikkerheden, tolerabiliteten og farmakokinetikken af ​​FF/UMEC/VI med FF/VI hos 12-17-årige deltagere med Utilstrækkeligt kontrolleret astma på stabil vedligeholdelsesterapi med ICS/LABA

The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

138

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Buenos Aires, Argentina, C1425BEN
        • GSK Investigational Site
      • Buenos Aires, Argentina, C1202
        • GSK Investigational Site
      • Buenos Aires, Argentina, 1888
        • GSK Investigational Site
      • Buenos Aires, Argentina, 1122
        • GSK Investigational Site
      • Buenos Aires, Argentina, C1023AAB
        • GSK Investigational Site
      • Córdoba, Argentina, X5000DCE
        • GSK Investigational Site
      • Córdoba, Argentina, X5014AKM
        • GSK Investigational Site
      • Lanus, Argentina, B1824KAJ
        • GSK Investigational Site
      • Lobos, Argentina, 7240
        • GSK Investigational Site
      • Lujan de Cuyo, Argentina, 5509
        • GSK Investigational Site
      • Mar del Plata, Argentina, 7600
        • GSK Investigational Site
      • Rosario, Argentina, 2000
        • GSK Investigational Site
      • Rosario Provincia de Santa FE, Argentina, 2000
        • GSK Investigational Site
      • San Miguel de Tucumán, Argentina, T4000IHE
        • GSK Investigational Site
      • Santa Fe, Argentina, 3000
        • GSK Investigational Site
    • Queensland
      • South Brisbane, Queensland, Australien, 4101
        • GSK Investigational Site
    • South Australia
      • North Adelaide, South Australia, Australien, 5006
        • GSK Investigational Site
    • Western Australia
      • Joondalup WA, Western Australia, Australien, 6027
        • GSK Investigational Site
      • Lo Barnechea, Chile, 7691236
        • GSK Investigational Site
      • Santiago, Chile, 7630000
        • GSK Investigational Site
      • Santiago, Chile, 8320000
        • GSK Investigational Site
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35244
        • GSK Investigational Site
      • Mobile, Alabama, Forenede Stater, 36608
        • GSK Investigational Site
    • Arizona
      • Paradise Valley, Arizona, Forenede Stater, 85253
        • GSK Investigational Site
    • California
      • Bakersfield, California, Forenede Stater, 93301-4205
        • GSK Investigational Site
      • Huntington Beach, California, Forenede Stater, 92647
        • GSK Investigational Site
      • Mission Viejo, California, Forenede Stater, 92691
        • GSK Investigational Site
      • Rolling Hills Estates, California, Forenede Stater, 90274
        • GSK Investigational Site
    • Colorado
      • Colorado Springs, Colorado, Forenede Stater, 80909
        • GSK Investigational Site
    • Florida
      • Aventura, Florida, Forenede Stater, 33180
        • GSK Investigational Site
      • Miami, Florida, Forenede Stater, 33173
        • GSK Investigational Site
      • Miami, Florida, Forenede Stater, 33165
        • GSK Investigational Site
      • Miami, Florida, Forenede Stater, 33174
        • GSK Investigational Site
    • Georgia
      • Savannah, Georgia, Forenede Stater, 31406
        • GSK Investigational Site
    • Illinois
      • Normal, Illinois, Forenede Stater, 61761
        • GSK Investigational Site
    • Kentucky
      • Owensboro, Kentucky, Forenede Stater, 42301
        • GSK Investigational Site
    • Missouri
      • Columbia, Missouri, Forenede Stater, 65203
        • GSK Investigational Site
    • Montana
      • Missoula, Montana, Forenede Stater, 59808
        • GSK Investigational Site
    • New York
      • The Bronx, New York, Forenede Stater, 10461-1119
        • GSK Investigational Site
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45229
        • GSK Investigational Site
      • Cleveland, Ohio, Forenede Stater, 44106
        • GSK Investigational Site
      • Dayton, Ohio, Forenede Stater, 45404
        • GSK Investigational Site
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73120-9350
        • GSK Investigational Site
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 29420
        • GSK Investigational Site
    • Texas
      • Dallas, Texas, Forenede Stater, 75225-6301
        • GSK Investigational Site
      • Kerrville, Texas, Forenede Stater, 78028
        • GSK Investigational Site
      • Plano, Texas, Forenede Stater, 75034
        • GSK Investigational Site
      • Waco, Texas, Forenede Stater, 76712
        • GSK Investigational Site
    • Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • GSK Investigational Site
      • Ashkelon, Israel, 7830604
        • GSK Investigational Site
      • Haifa, Israel, 3436212
        • GSK Investigational Site
      • Haifa, Israel, 3109600
        • GSK Investigational Site
      • Petah Tikva, Israel, 49202
        • GSK Investigational Site
      • Guadalajara, Mexico, 44100
        • GSK Investigational Site
      • Monterrey, Mexico, 64460
        • GSK Investigational Site
      • San Juan del Río, Mexico, 76800
        • GSK Investigational Site
    • Upper Hutt
      • Ebdentown, Upper Hutt, New Zealand, 5018
        • GSK Investigational Site
      • Cheongju Chungcheongbuk-do, Sydkorea, 28644
        • GSK Investigational Site
      • Gwangju, Sydkorea, 501-757
        • GSK Investigational Site
      • Seoul, Sydkorea, 05505
        • GSK Investigational Site
      • Seoul, Sydkorea, 03722
        • GSK Investigational Site
      • Seoul, Sydkorea, 1757
        • GSK Investigational Site
      • Seoul, Sydkorea, 2447
        • GSK Investigational Site
      • Adana, Tyrkiet (Türkiye), 1173
        • GSK Investigational Site
      • Antalya, Tyrkiet (Türkiye), 07070
        • GSK Investigational Site
      • Istanbul, Tyrkiet (Türkiye), 34010
        • GSK Investigational Site
      • Istanbul, Tyrkiet (Türkiye), 34899
        • GSK Investigational Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

12 år til 17 år (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Participant must be 12 to 17 years of age (inclusive), at the time of signing the informed consent/assent.
  • Participants who have a diagnosis of asthma as defined by the National Institutes of Health [NIH, 2020] at least 1 year prior to Visit 0.
  • Participants who have required daily Inhaled corticosteroids (ICS)/ Long-Acting Beta2-Agonist (LABA) treatment for at least 12 weeks prior to Visit 0 with no changes to maintenance asthma medications during the 6 weeks immediately prior to Visit 0 (including no changes to a stable total ICS dose of >250 to <=500 microgram (mcg)/day fluticasone propionate, or equivalent).
  • In the 1 year prior to Visit 1: A documented healthcare contact for acute asthma symptoms; OR A documented temporary change in asthma therapy for acute asthma symptoms, according to a prespecified asthma action plan (or equivalent).
  • Participants with inadequately controlled asthma (ACQ-6 score ≥1.5) at Visit 1, despite ICS/LABA maintenance therapy.
  • A best pre-bronchodilator FEV1 >40% to <=90% of the predicted normal value and a ≥12% increase in FEV1 with albuterol/salbutamol at Visit 1. Predicted values will be based on the European Respiratory Society (ERS) Global Lung Function Initiative.

Exclusion Criteria:

  • Chest X-ray documented pneumonia in the 6 weeks prior to Visit 1.
  • Any asthma exacerbation requiring a change in maintenance asthma therapy and/or the use of systemic corticosteroids for at least 3 days in the 6 weeks prior to Visit 1. (Participants requiring a temporary change in asthma therapy (e.g., oral corticosteroids or increased dose of ICS) to treat an exacerbation in the 6 weeks prior to Visit 1 are not explicitly excluded at Visit 1 provided that, at the Investigator's discretion, the participant's condition is stable after they have resumed their pre-exacerbation maintenance asthma therapy (without modification), returned to their baseline asthma status and they are considered appropriate for enrollment into this study of up to 6 months duration)
  • History of Life-threatening Asthma
  • Participants with current evidence of active pulmonary diseases or abnormalities other than asthma (e.g., pneumonia, active tuberculosis, significant bronchiectasis, etc.).
  • Current smokers and users of other inhaled products for recreation with or without nicotine (defined as participants who use cigarettes, e-cigarettes, other/vaping-related devices, cigars or pipe tobacco]) within 12 months prior to Visit 1.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Deltagere, der modtager FF/UMEC/VI

FF/UMEC/VI will be administered.

FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler

Aktiv komparator: Deltagere, der modtager FF/VI

FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler

FF/VI will be administered.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change from baseline in trough forced expiratory volume in 1 second (FEV1) (Liters) at Week 24
Tidsramme: Baseline (Week 0) and Week 24

FEV1 will be measured using spirometry.

Baseline (Week 0) and Week 24

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change from Baseline in Asthma Control Questionnaire (7 items) (ACQ-7) (Scores on a scale)
Tidsramme: Baseline (Week 0) and Week 24

ACQ-7 consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation)), a question on rescue use and an additional item relating to lung function which is calculated based on FEV1. A score of less than or equal to (<=) 0.75 indicates well-controlled asthma and a score greater than or equal to (>=)1.5 indicates poorly controlled asthma.

Baseline (Week 0) and Week 24
Change from Baseline in Asthma Control Questionnaire (6 items) (ACQ-6) (Scores on a scale)
Tidsramme: Baseline (Week 0) and Week 24

ACQ-6 consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation)) and a question on rescue bronchodilator use. A score of less than or equal to (<=) 0.75 indicates well-controlled asthma and a score greater than or equal to (>=)1.5 indicates poorly controlled asthma.

Baseline (Week 0) and Week 24
Change from Baseline in Asthma Control Questionnaire (5 items) (ACQ-5) (Scores on a scale)
Tidsramme: Baseline (Week 0) and Week 24

ACQ-5 consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of less than or equal to (<=) 0.75 indicates well-controlled asthma and a score greater than or equal to (>=)1.5 indicates poorly controlled asthma.

Baseline (Week 0) and Week 24
Number of Participants with a clinically important change from baseline in ACQ-7 Score
Tidsramme: Week 24

ACQ-7 consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation)), a question on rescue use and an additional item relating to lung function which is calculated based on FEV1. A score of less than or equal to (<=) 0.75 indicates well-controlled asthma and a score greater than or equal to (>=)1.5 indicates poorly controlled asthma. A change of 0.5 in score suggests a clinically important change in score.

Week 24
Number of Participants with a clinically important change from baseline in ACQ-6 Score
Tidsramme: Week 24

ACQ-6 consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation)) and a question on rescue bronchodilator use. A score of less than or equal to (<=) 0.75 indicates well-controlled asthma and a score greater than or equal to (>=)1.5 indicates poorly controlled asthma. A change of 0.5 in score suggests a clinically important change in score.

Week 24
Number of Participants with a clinically important change from baseline in ACQ-5 Score
Tidsramme: Week 24

ACQ-5 consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of less than or equal to (<=) 0.75 indicates well-controlled asthma and a score greater than or equal to (>=)1.5 indicates poorly controlled asthma. A change of 0.5 in score suggests a clinically important change in score.

Week 24

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: GSK Clinical Trials, GlaxoSmithKline

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

24. april 2023

Primær færdiggørelse (Anslået)

26. januar 2027

Studieafslutning (Anslået)

28. januar 2027

Datoer for studieregistrering

Først indsendt

24. februar 2023

Først indsendt, der opfyldte QC-kriterier

24. februar 2023

Først opslået (Faktiske)

7. marts 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 206867

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

IPD-delingstidsramme

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

IPD-delingsadgangskriterier

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .